Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Clayton C, Austin G, Palmer BE, Zheng JH, Klein B, Kerr BJ, Guida LA, Rower C, Rower JE, Kiser JJ, Bushman LR, MaWhinney S, Anderson PL.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):981-991. Epub 2016 Sep 19.

2.

Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.

Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Rower C, Klein B, Kerr BJ, Guida LA, Zheng JH, Bushman LR, Anderson PL.

Clin Infect Dis. 2015 Mar 1;60(5):804-10. doi: 10.1093/cid/ciu916. Epub 2014 Nov 18. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

3.

Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.

Aquilante CL, Wempe MF, Spencer SH, Kosmiski LA, Predhomme JA, Sidhom MS.

Pharmacotherapy. 2013 Sep;33(9):1000-7. doi: 10.1002/phar.1292. Epub 2013 May 26.

4.

Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.

Aquilante CL, Wempe MF, Sidhom MS, Kosmiski LA, Predhomme JA.

Eur J Clin Pharmacol. 2013 Jul;69(7):1401-9. doi: 10.1007/s00228-013-1475-y. Epub 2013 Feb 14.

5.

Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers.

Hammond KP, Wolfe P, Burton JR Jr, Predhomme JA, Ellis CM, Ray ML, Bushman LR, Kiser JJ.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):67-73. doi: 10.1097/QAI.0b013e318275da93.

PMID:
23075915
6.

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS.

Br J Clin Pharmacol. 2013 Jan;75(1):217-26. doi: 10.1111/j.1365-2125.2012.04343.x.

7.

Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.

Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS.

J Clin Pharmacol. 2012 Nov;52(11):1725-38. doi: 10.1177/0091270011427907. Epub 2011 Dec 14.

PMID:
22174437
8.

Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.

Kiser JJ, Bumpass JB, Meditz AL, Anderson PL, Bushman L, Ray M, Predhomme JA, Rower J, Mawhinney S, Brundage R.

Antimicrob Agents Chemother. 2010 Dec;54(12):4999-5003. doi: 10.1128/AAC.00636-10. Epub 2010 Oct 4.

9.

Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.

Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):570-8. doi: 10.1097/QAI.0b013e318160a542.

PMID:
18176327

Supplemental Content

Loading ...
Support Center